Maxim Group Maintains Buy on Vistagen Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has maintained a 'Buy' rating on Vistagen Therapeutics (NASDAQ:VTGN) and kept the price target at $30.
September 05, 2023 | 7:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics has maintained its 'Buy' rating from Maxim Group, with a steady price target of $30.
The maintained 'Buy' rating and price target by Maxim Group indicates a positive outlook for Vistagen Therapeutics. This could potentially attract investors, leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100